SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: vestor who wrote (1179)5/12/1999 3:13:00 PM
From: vestor  Read Replies (2) of 1837
 
From the conf call:
1- Approval of BC ANDA in the next few weeks.
2- All three ANDA's approved in the next few weeks.
3- Current market for all DRMD existing and in-pipeline products is billion with growth to 6 - 8 billion in 3 5- yrs.
4- Cardinal will initially have 125 reps. for Cenestin.
5- Pre-book orders for Cenestin are stong and accelerating.
6- Professional promotion begins 6/1.
National detailing begins 7/1.
7- Expect approval of 1.25 Cenestin dosage by 4th qtr.
8- Bone mamarrow study to be complete by 11/99.
9- Treatment for Osteo (Cenestin) expected within 24 months.
10- Dillin Reid conf. call 5/25.
11- Merrill Lynch, positive comments, possible coverage soon ?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News